Printer Friendly

U.S. PATENT OFFICE GRANTS PATENT ON CERESTAT (CNS 1102)

 CAMBRIDGE, Mass., July 13 /PRNewswire/ -- Cambridge NeuroScience, Inc. (NASDAQ: CNSI) today announced that the U.S. Patent and Trademark Office has allowed the patent application for Cerestat(tm), the company's lead neuroprotective compound. Cerestat is currently undergoing clinical development by Cambridge NeuroScience for the treatment of stroke.
 The patent allowance covers the composition of matter of Cerestat (CNS 1102) as well as back up compounds and other similar chemical structures that number over 100 different compounds.
 Phase Ia studies of Cerestat in human volunteers have been completed in the United Kingdom. Phase Ib studies are now underway at six medical centers in New England to evaluate the safety of the product in stroke patients. The company plans to launch an even more aggressive clinical trial development program for Cerestat in coming weeks.
 Cambridge NeuroScience is a leading neuroscience company engaged in the discovery and development of proprietary pharmaceuticals with a focus on nerve cell survival. The company is developing a number of products to treat stroke, traumatic brain injury, schizophrenia and chronic neurodegenerative disorders such as diabetic peripheral neuropathy and multiple sclerosis.
 -0- 7/13/93
 /CONTACT: Philip V. Holberton, chief financial officer, Cambridge NeuroScience, 617-225-0600; Marcia A. Kean, executive vice president, Feinstein Partners Inc., 617-577-8110, for Cambridge NeuroScience/
 (CNSI)


CO: Cambridge NeuroScience, Inc. ST: Massachusetts IN: MTC SU:

DJ-CM -- NE003 -- 0837 07/13/93 11:05 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 13, 1993
Words:228
Previous Article:REA GOLD CORP. SOUTH COMSTOCK JOINT VENTURE PROCEEDING AHEAD OF SCHEDULE
Next Article:ARTHUR D. LITTLE/WEFA GROUP RESEARCH FINDS: MOST AMERICANS FACE HUGE SHORTFALL IN RETIREMENT INCOME, BUT TAX-ADVANTAGED PLANS, ASSET SHIFTS CAN HELP...
Topics:


Related Articles
CAMBRIDGE NEUROSCIENCE TO BEGIN U.S. CLINICAL TRIALS OF CERESTAT IN STROKE PATIENTS
CAMBRIDGE NEUROSCIENCE RECEIVES U.S. PATENTS ON CERESTAT AND RELATED NEUROPROTECTIVE COMPOUNDS
PROMISING RESULTS REPORTED ON CAMBRIDGE NEUROSCIENCE'S CERESTAT
Innapharma's Patent for Peptide Antidepressants
NeuralSTEM Biopharmaceuticals Announces Issuance of U.S. Patent Covering Company's CNS Stem Cell Technology
Hemispherx Patents a Diagnostic for Cognitive Disorder.
Epilepsy patent issued to Neurochem.
Arena Pharmaceuticals Issued Patent for 5-HT2C Receptor Modulators by United States Patent Office.
Patent granted to ScinoPharm for production of irinotecan intermediate.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters